Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Newron Pharmaceuticals SpA's Enterprise Value is €289.23 Mil.
Newron Pharmaceuticals SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.96 Mil. Therefore, Newron Pharmaceuticals SpA's EV-to-EBIT ratio for today is -36.35.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Newron Pharmaceuticals SpA (FRA:NP5) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Newron Pharmaceuticals SpA's EV-to-EBIT for today is
Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.96 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Newron Pharmaceuticals SpA's EV-to-EBITDA for today is:
Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.78 Mil.
Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €19.13 Mil.
Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €32.35 Mil.
Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €32.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA Enterprise Value Related Terms
Newron Pharmaceuticals SpA Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NP5 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's Enterprise Value falls into.
Newron Pharmaceuticals SpA Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Newron Pharmaceuticals SpA's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA (FRA:NP5) has a Enterprise Value of €289.23 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Enterprise Value too high?
Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Enterprise Value compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Enterprise Value of €289.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Enterprise Value is €289.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.49, compared to a current price of €13.95 — trading 3.4% above its estimated fair value. The current Enterprise Value is €289.23 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Enterprise Value is €289.23 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be overvalued.
The current stock price of €13.95 is trading 3.4% above its estimated GF Value™ of €13.49.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for FRA:NP5:
Enterprise Value: €289.23 Mil
GF Value™: €13.49 vs. price of €13.95 (3.4% above fair value)
No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score
Get the complete analysis for FRA:NP5
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NP5 has been successfully added to your 
